Results 291 to 300 of about 495,708 (385)

Hypnotic doses of fazamorexant induced less impairment on balance and cognition than zolpidem in healthy younger and elderly individualse

British Journal of Clinical Pharmacology, EarlyView.
Aims Fazamorexant is a dual orexin receptor antagonist being developed for the treatment of insomnia. This study aims to determine the dose‐exposure‐response relationship of single‐dose fazamorexant vs. zolpidem in young adult and elderly healthy Chinese volunteers. Methods This single‐centre, randomized, double‐blind, double‐dummy, placebo‐ and active‐
Chen Xia, Huang Xingxing, Jin Lu, Wang Ruwei   +3 more
wiley   +1 more source

Revolutionizing Chinese medicine granule placebo with a machine learning four-color model. [PDF]

Chin Med
Teng T, Zhang J, Miao P, Liang L, Song X, Liu D, Zhang J.   +6 more
europepmc   +1 more source

Risk of gastrointestinal bleeding by specific SSRIs and SNRIs: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to estimate the risk of gastrointestinal bleeding (GIB) by selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs) individual agents. Methods A systematic review was conducted for each unique antidepressant (i.e.
Ainhoa Gomez‐Lumbreras, Abdelrahman G. Tawfik, Guilherme Del Fiol, Kensaku Kawamoto, Thomas Reese, Katy Trinkley, Aubrey Jones, James Mitchell, Daniel C. Malone   +8 more
wiley   +1 more source

Acute and prolonged toxicity assessment of Cannabis sativa extract in rodents and lagomorphs. [PDF]

Toxicol Rep
Costa AC, Gasparotto A, Garcia AAK, Pereira CAC, Lourenço ELB, Joaquim HPG.   +5 more
europepmc   +1 more source

Model‐informed drug development to support nemolizumab clinical development in adults and adolescents with moderate to severe atopic dermatitis

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Population pharmacokinetic (popPK) and pharmacokinetic‐pharmacodynamic (PK/PD) models were developed to support clinical development of nemolizumab, a humanized monoclonal antibody targeting the IL‐31 receptor α, in adolescents and adults with moderate‐to‐severe atopic dermatitis (AD).
Floris Fauchet, Anna Largajolli, Petra M. Jauslin, Emilie Schindler, Mourad Hamimed, Wannee Kantasiripitak, Antonio Gonçalves, Eline Van Maanen, Khaled Benkali, Tomohisa Saito, Jonathan I. Silverberg, Andreas Wollenberg, Michael Graeber, Liliana Ulianov, Christophe Piketty, Luca Loprete, Vincent Duval, Nathalie Wagner   +17 more
wiley   +1 more source

Conditioned open-label placebos to facilitate opioid reduction in patients with chronic non-cancer pain: study protocol of a randomised controlled trial. [PDF]

BMJ Open
Carratta K, Bodonyi K, Frey Nascimento A, Friis D, von Känel R, Bircher L, Koechlin H, Bernstein M, Streitberger K, Arnet I, Roth AJ, Ronel J, Olliges E, Locher C.   +13 more
europepmc   +1 more source

Predictors of post-operative response to treatment: a double blind placebo controlled study in chronic rhinosinusitis patients

, 2011
Fenna A. Ebbens, Sanna Toppila‐Salmi, E. J. J. De Groot, Jutta Renkonen, Risto Renkonen, Cornelis M. van Drunen, M.G.W. Dijkgraaf, Wytske J. Fokkens   +7 more
openalex   +2 more sources

Risk of cardiac, neuropsychiatric and musculoskeletal adverse events with levothyroxine: Systematic review

British Journal of Clinical Pharmacology, EarlyView.
Abstract Levothyroxine (LT4) is the standard treatment for hypothyroidism and the most widely prescribed medication worldwide. Although generally safe, regulatory reports list potential cardiac, neuropsychiatric and musculoskeletal adverse events (AEs). Clarifying their clinical relevance is essential.
Bala Swetha Baskaran, Mohammad Ali Omrani, Flory T. Muanda   +2 more
wiley   +1 more source

Main factors associated with variability in the assessment of the objective response rate. A re‐analysis of the PHEREXA phase 3 clinical trial

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Local investigators (LIs) overestimate the objective response rate (ORR) in comparison to Blinded Independent Central Reviewers (BICR) in oncology. In this study, we re‐analysed data obtained in the PHEREXA trial (NCT01026142) with the following aims: i) to confirm at the single‐patient level the discrepancy observed by analysing ...
Gennaro Daniele, Tommaso Giovagnoli, Pierluigi Navarra, Cinzia Dello Russo   +3 more
wiley   +1 more source

Use of DNA profiling to resolve HIV status in a person using injectable cabotegravir for HIV pre-exposure prophylaxis. [PDF]

J Clin Pathol
Fogel JM, Salih MA, Haddaway K, Marzinke MA, Marshall C, Wang Z, Cummings V, Piwowar-Manning E, Rooney JF, McCauley M, Grinsztejn B, Landovitz RJ, Eshleman SH.   +12 more
europepmc   +1 more source